Mark Beamer, MD
Family Medicine · Belhaven, NCNPI 1053426346
Payments from drug & device makers
Across 627 payments — averaging $17.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$2K
- AstraZeneca$1K
- GSK$1K
- AbbVie$653
- Pfizer$531
- plus $4K from 31 others
What the payments were for
- Food & beverage$10,843100%
- Education$400%
- Other$100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 152 | $1,960 |
| Amgen | 86 | $1,672 |
| AstraZeneca | 36 | $1,312 |
| GSK | 60 | $1,012 |
| AbbVie(2 entities) | 31 | $653 |
| Pfizer | 45 | $531 |
| Lilly USA, LLC | 27 | $462 |
| Dexcom, Inc. | 11 | $399 |
| Abbott | 29 | $336 |
| Johnson & Johnson | 29 | $319 |
| Sanofi-aventis U.S. LLC | 22 | $318 |
| Corcept Therapeutics | 10 | $300 |
| Boehringer Ingelheim | 14 | $179 |
| Astellas Pharma US Inc | 11 | $176 |
| Bayer | 10 | $169 |
| Merck | 12 | $168 |
| Phathom Pharmaceuticals, Inc. | 3 | $165 |
| Novartis | 10 | $161 |
| Sonex Health, Inc. | 1 | $129 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| Exact Sciences | 2 | $33 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Endo Pharmaceuticals Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Insulet Corporation | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Neotract Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Viatris Specialty LLC | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$489
- BREZTRI$264
- AIRSUPRA$264
- EVENITY$252
- Repatha$139
- VOQUEZNA$134
- Sx-One Microknife$129
- TRELEGY ELLIPTA$125
- AIMOVIG$125
- Korlym$114
- Wegovy$108
- QULIPTA$102
- UBRELVY$102
- DEXCOM G6 TRANSMITTER$102
How this compares
$10,893 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 143 | $207,080 |
| FarxigaDapagliflozin Propanediol | 176 | $126,813 |
| EliquisApixaban | 113 | $104,816 |
| MounjaroTirzepatide | 83 | $90,494 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 91 | $79,513 |
| XareltoRivaroxaban | 68 | $56,619 |
| JardianceEmpagliflozin | 31 | $49,724 |
| JanuviaSitagliptin Phosphate | 39 | $42,655 |
| MyrbetriqMirabegron | 56 | $34,066 |
| EntrestoSacubitril/Valsartan | 43 | $29,540 |
| TrulicityDulaglutide | 20 | $28,574 |
| KerendiaFinerenone | 14 | $26,861 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $21,290 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $13,523 |
| Bydureon BciseExenatide Microspheres | 14 | $13,235 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,960 | $207,080143 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,312 | $153,589225 claims |
| Lilly USA, LLCMounjaro, Trulicity | $462 | $119,068103 claims |
| PfizerEliquis | $531 | $104,816113 claims |
| GSKTrelegy Ellipta | $1,012 | $79,51391 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $179 | $58,96850 claims |
| MerckJanuvia, Janumet, Belsomra | $168 | $57,91062 claims |
| Johnson & JohnsonXarelto | $319 | $56,61968 claims |
| Astellas Pharma US IncMyrbetriq | $176 | $34,06656 claims |
| NovartisEntresto | $161 | $29,54043 claims |
| BayerKerendia | $169 | $26,86114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Belhaven
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.